KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) R&D In Process (2016 - 2017)

Teva Pharmaceutical Industries filings provide 3 years of R&D In Process readings, the most recent being $175.0 million for Q3 2017.

  • On a quarterly basis, R&D In Process fell 30.56% to $175.0 million in Q3 2017 year-over-year; TTM through Sep 2017 was $427.0 million, a 62.98% increase, with the full-year FY2009 number at $23.0 million, changed N/A from a year prior.
  • R&D In Process hit $175.0 million in Q3 2017 for Teva Pharmaceutical Industries, down from $252.0 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $252.0 million in Q3 2016 to a low of $10.0 million in Q1 2016.
  • Median R&D In Process over the past 3 years was $99.5 million (2015), compared with a mean of $115.2 million.
  • The widest YoY moves for R&D In Process: up 30.56% in 2017, down 30.56% in 2017.
  • Teva Pharmaceutical Industries' R&D In Process stood at $24.0 million in 2015, then soared by 950.0% to $252.0 million in 2016, then plummeted by 30.56% to $175.0 million in 2017.
  • The last three reported values for R&D In Process were $175.0 million (Q3 2017), $252.0 million (Q3 2016), and $10.0 million (Q1 2016) per Business Quant data.